Skip to main
ENGN

ENGN Stock Forecast & Price Target

ENGN Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 67%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

enGene Holdings Inc. has demonstrated promising advancements in its lead therapy, detalimogene, which has shown a six-month complete response (CR) rate comparable to leading treatments within the non-muscle invasive bladder cancer (NMIBC) space while benefiting from a non-viral delivery method that enhances safety and ease of use. The company's recent protocol amendments significantly improved CR rates, exceeding previous investor expectations and aligning with best-in-class therapies, which strengthens the potential for adoption among urologists for patients unresponsive to traditional treatments. Furthermore, with an updated discounted cash flow (DCF) analysis forecasting increased sales to $530 million by 2031, enGene Holdings highlights a strong growth trajectory, bolstered by the favorable clinical profile and rising conviction among healthcare professionals.

Bears say

enGene Holdings Inc. is facing significant challenges that negatively impact its stock outlook, primarily due to disappointing performance in the ongoing LEGEND trial, with observed complete response (CR) rates significantly lower than initially anticipated. Unexpected safety issues and changes in regulatory requirements for non-muscle invasive bladder cancer (NMIBC) approvals add further uncertainty to the company's potential for successful drug development. Additionally, the anticipated need for higher capital, potentially leading to increased equity dilution, poses financial risks that could undermine shareholder value.

ENGN has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 67% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Engene Holdings Inc (ENGN) Forecast

Analysts have given ENGN a Buy based on their latest research and market trends.

According to 6 analysts, ENGN has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Engene Holdings Inc (ENGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.